Navigation Links
Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis
Date:4/14/2009

WOBURN, Mass., April 14 /PRNewswire/ -- Intrinsic Therapeutics, Inc. announced today that it has received a CE mark for its Barricaid(R) anular prosthesis for use in reconstructing soft tissues of the spine. The CE mark gives Intrinsic approval to distribute the Barricaid throughout the European Union and in other countries that recognize the CE mark.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090414/NE98588LOGO )

"We are very pleased with receiving the CE mark and believe that this event reflects, in part, on the very positive clinical results in our current, prospective clinical study of the Barricaid anular prosthesis," stated Barry Sands, Vice President Regulatory, Clinical, and Quality Affairs. The Barricaid (www.in-thera.com) is a revolutionary partial disc prosthesis that enables surgeons to directly reconstruct the anulus of the intervertebral disc in patients with lumbar disc herniations and sciatica as part of a standard, minimal access discectomy procedure. More than 500,000 discectomies are performed worldwide each year.

"This approval gives Intrinsic the opportunity to offer surgeons, patients, and payers the potential for a truly better outcome in the treatment of lumbar disc herniation, the most common degenerative condition of the spine," stated Greg Lambrecht, President & CEO. "The Barricaid and its approval in the European Union is the culmination of years of extensive pre-clinical and clinical development to address this fundamental, unmet need in spine surgery. Surgeons have tried many different techniques over the years to repair the anulus including sutures, glues, and clips with very limited success. The Barricaid offers a new surgical strategy by reconstructing the anulus and anchoring it to the vertebral body for a more secure solution. Intrinsic and the surgeons we serve are very excited by the positive results from the initial clinical study of the Barricaid that helped us reach this important milestone."

About Intrinsic Therapeutics

Intrinsic Therapeutics is dedicated to treating soft-tissue injuries of the spine. Intrinsic's Barricaid anular reconstructive products are used during discectomy to definitively close defects in the posterior anulus. By restoring anular competence, the Barricaid family of products may reduce the risk of recurrent herniation while maintaining disc height and biomechanics.

    Contacts:
    Scott LeBlanc                               Tom Guest
    Director Finance                            VP Sales & Marketing
    Intrinsic Therapeutics, Inc.                Intrinsic Therapeutics, Inc.
    781-932-0222 ext. 173                       781-932-0222 ext. 133
    finance@in-thera.com


'/>"/>
SOURCE Intrinsic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: